University of Basel

Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls

Start Date

June 1, 2026

Compounds

MDMA, Placebo

Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants

Start Date

March 31, 2026

Compounds

5-MeO-DMT, Placebo

Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants

Start Date

March 9, 2026

Compounds

MDMA, Placebo

Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD

Start Date

January 1, 2026

Compounds

LSD, Placebo

Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants (R-S-)

Start Date

May 1, 2025

Compounds

MDMA, Placebo

Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects (MDMA-Psilo)

Start Date

April 1, 2025

Compounds

Psilocybin, Placebo, MDMA

Antidepressant Response of DMT Masked With Propofol (DMT4D)

Start Date

April 1, 2025

Compounds

DMT, Placebo

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants (LPD)

Start Date

April 1, 2025

Compounds

LSD, Psilocybin, DMT, Placebo

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness

Start Date

February 1, 2025

Compounds

Psilocybin, Placebo

Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls (OxyMAX)

Start Date

January 1, 2025

Compounds

MDMA, Placebo

Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants

Start Date

May 1, 2024

Compounds

DMT, Ketamine, Placebo

LSD-Perceptual-Choice-Study (LUCY)

Start Date

February 20, 2024

Compounds

LSD, Placebo

Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects (LBL)

Start Date

February 1, 2024

Compounds

LSD, Placebo

Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose

Start Date

November 17, 2023

Compounds

MDMA, Placebo

Lysergic Acid Diethylamide (LSD) in Palliative Care (LPC)

Start Date

September 1, 2023

Compounds

LSD

Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study) (DMT BDR)

Start Date

March 15, 2023

Compounds

DMT, Placebo

LSD Treatment for Persons With Alcohol Use Disorder (LYSTA)

Start Date

January 1, 2023

Compounds

LSD

Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects (2C-B)

Start Date

December 31, 2022

Compounds

2C-X, MDMA, Psilocybin, Placebo

Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT DR)

Start Date

September 1, 2022

Compounds

DMT, Placebo

Acute Effects of R- and S-MDMA in Healthy Subjects (R-S-MDMA)

Start Date

June 30, 2022

Compounds

MDMA, Placebo

Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects

Start Date

December 1, 2020

Compounds

DMT, Placebo

LSD Therapy for Persons Suffering From Major Depression

Start Date

January 11, 2019

Compounds

LSD

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants

This double-blind, randomised, placebo-controlled crossover study (n=24) in healthy adults compared acute effects of 2C-B, MDMA and psilocybin. A 30 mg dose of 2C-B produced effects similar to MDMA and some psychedelic changes, while MDMA caused the strongest cardiovascular stimulation and psilocybin caused more anxiety and unpleasant effects.

Published

April 28, 2026

Journal

Neuropsychopharmacology

Authors

Arikci, D., Borgulya, J., Straumann, I., Vizeli, P., Luethi, D., Thomann, J., Rudin, D., Vukalovic, I., Eckert, A., Liechti, M. E., Holze, F.

Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness—a psychometric analysis using the PES100 in controlled psychedelic studies

This psychometric analysis using the PES100 examined 816 measurements from healthy participants (n=386) across 15 controlled psychedelic studies of LSD, psilocybin, mescaline and DMT. It found that mystical oneness was strongly linked to feelings of luminous light and renewal, and moderately to strongly linked to ego disintegration, with these links increasing with dose.

Published

March 31, 2026

Journal

Religion, Brain & Behavior

Authors

Stocker, K., Hartmann, M., Barrett, F. S., Richards, W., Sepeda, N. D., Straumann, I., Klaiber, A., Vogt, S. B., Erne, L., Ley, L., Becker, A. M., Vizeli, P., Holze, F., Liechti, M. E.

Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants

This double-blind, randomised, placebo-controlled crossover study and separate open-label dose-escalation study (n=36) in healthy participants examined intravenous DMT and found that it produced very strong but short-lived subjective effects, peaking within 2 minutes and fading within 12 to 30 minutes. The strongest effects levelled off at 15 mg, and dose escalation appeared to improve tolerability compared with blinded dosing.

Published

March 27, 2026

Journal

Translational Psychiatry

Authors

Erne, L., Mueller, L., Straumann, I., Ademaj, B., Eckert, A., Vukalovic, I., Valenta, J., Luethi, D., Liechti, M. E., Vogt, S. B.

Safety pharmacology of acute mescaline administration in healthy participants

This pooled analysis of two double‑blind, randomized, placebo‑controlled studies (48 participants, 96 administrations) found that single oral doses of mescaline 100–800 mg produced dose‑dependent increases in positive subjective effects with only moderate autonomic changes and no clinically significant liver, kidney or haematological abnormalities. Although nausea was dose‑limiting and small proportions experienced transient diastolic hypertension, tachycardia, fever or “flashbacks”, single doses up to 800 mg were considered safe with respect to acute psychological and physical harm in healthy participants in a controlled clinical setting.

Published

November 25, 2024

Journal

British Journal of Clinical Pharmacology

Authors

Klaiber, A., Humbert‐Droz, M., Ley, L., Schmid, Y., Liechti, M. E.

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

In a randomised, double‑blind, placebo‑controlled crossover study (n=32) in healthy volunteers, mescaline (300/500 mg), LSD (100 µg), and psilocybin (20 mg) produced comparable acute subjective effects with no qualitative differences in altered states of consciousness at psychoactive‑equivalent doses. Pharmacokinetic differences explained duration differences (mescaline ≈11.1 h, LSD ≈8.2 h, psilocybin ≈4.9 h), with modest autonomic and oxytocin effects (mescaline and LSD increased oxytocin) and similar tolerability apart from slightly more subacute adverse effects after mescaline.

Published

May 25, 2023

Journal

Neuropsychopharmacology

Authors

Ley, L., Holze, F., Arikci, D., Becker, A. M., Straumann, I., Klaiber, A., Coviello, F., Dierbach, S., Thomann, J., Duthaler, U., Luethi, D., Varghese, N., Eckert, A., Liechti, M. E.